Equillium, Inc. reported its financial results for the third quarter of 2025, revealing a significant decline in revenue and an increase in operating losses compared to the same period in the previous year. The company did not generate any revenue during the three and nine months ended September 30, 2025, a stark contrast to the $12.2 million and $36.7 million reported for the same periods in 2024. This drop in revenue is attributed to the expiration of an Asset Purchase Agreement with Ono Pharmaceutical Co., which had provided development funding and upfront payments for the rights to itolizumab.
Operating expenses for Equillium decreased to $4.6 million in the third quarter of 2025 from $12.8 million in the same quarter of 2024. This reduction was primarily driven by a significant decrease in research and development expenses, which fell to $1.3 million from $9.6 million year-over-year. The company attributed this decline to the winding down of clinical studies and negotiated discounts with clinical vendors. General and administrative expenses remained relatively stable, totaling $3.3 million for the third quarter of 2025, compared to $3.3 million in the prior year.
Equillium's net loss for the third quarter was $4.2 million, compared to a net loss of $0.007 million in the same quarter of 2024. For the nine months ended September 30, 2025, the net loss was $18.6 million, significantly higher than the $2.3 million loss reported for the same period in 2024. The company’s accumulated deficit reached $212.4 million as of September 30, 2025, reflecting ongoing investments in research and development without corresponding revenue generation.
In terms of strategic developments, Equillium completed a private placement in August 2025, raising approximately $30 million through the sale of common stock and pre-funded warrants. This financing is intended to support the development of EQ504, a novel aryl hydrocarbon receptor modulator, which the company plans to advance into a Phase 1 clinical study by mid-2026. Additionally, Equillium terminated its collaboration with Biocon Limited on September 30, 2025, reverting all rights related to itolizumab back to Biocon.
Looking ahead, Equillium anticipates continued operating losses as it invests in the development of EQ504 and potentially other product candidates. The company expects its existing cash and cash equivalents of $33.1 million will fund operations through at least 2027. However, it acknowledges the need for additional capital to support ongoing research and development activities, which may be impacted by various macroeconomic factors and market conditions.
About Equillium, Inc.
Equillium, Inc. is a biotechnology company focused on developing novel immuno-inflammatory therapeutics. Its pipeline includes first-in-class monoclonal antibodies and multi-cytokine inhibitors targeting severe autoimmune and inflammatory diseases such as graft-versus-host disease, celiac disease, and alopecia areata. The company leverages proprietary platforms and strategic partnerships to advance clinical candidates and aims to commercialize therapies that address high unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.